GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » Cash From Other Investing Activities

Everest Medicines (STU:6HN) Cash From Other Investing Activities : €-0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Everest Medicines Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Everest Medicines's cash from other investing activities for the six months ended in Dec. 2024 was €-0.04 Mil. It means Everest Medicines spent €0.04 Mil on other investing activities. Everest Medicines's cash from other investing activities for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.00 Mil.

Everest Medicines Cash From Other Investing Activities Historical Data

The historical data trend for Everest Medicines's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Cash From Other Investing Activities Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash From Other Investing Activities
Get a 7-Day Free Trial - - - 0.80 -

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -157.11 - 0.85 0.04 -0.04

Everest Medicines Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » Cash From Other Investing Activities
Comparable Companies
HKSE:06826 HKSE:02171 HKSE:02162 HKSE:06855 HKSE:09606 HKSE:09966 HKSE:02410 HKSE:02629 HKSE:00775 HKSE:02105 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
01952:Hong Kong 6HN:Germany
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Website
https://www.everestmedicines.com
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.

Everest Medicines Headlines

No Headlines